SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Encouraging early zugo-cel data in autoimmune diseases is drawing attention: traders highlight responses in systemic sclerosis and inflammatory myopathy, alongside a favorable initial safety read across 21 patients. Bulls see promise in the off-the-shelf CD19 CAR-T approach, while others stress that the small cohorts and early follow-up leave efficacy and safety to be confirmed.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

EWY is rebounding with South Korean equities and memory-chip stocks after a sharp AI-related selloff and forced deleveraging. Traders are debating whether the bounce signals stabilization or is temporary, with KOSPI volatility keeping sentiment cautious.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Traders are focused on volatility and correction risk across the Nasdaq and technology stocks, citing macroeconomic and geopolitical uncertainty alongside concerns about elevated valuations. The discussion is divided between bearish calls for further declines and dip-buyers expecting a rebound; options-flow commentary is mixed rather than a clear consensus.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on Alpha Taus clinical pipeline: traders are watching for further REGAIN glioblastoma data, updates from the completed-enrollment IMPACT pancreatic trial, ReSTART results, and a possible FDA IDE for the Keytruda combination. The community is broadly bullish on the upcoming milestones and recent share-price strength, though some are waiting for confirmed updates rather than speculating about the next announcement.

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,805,873.7130931 in circulation. The last known price of Litecoin is 52.00804602 USD and is down -0.75 over the last 24 hours. It is currently trading on 1567 active market(s) with $117,565,973.29 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoins pullback and weak performance after earlier rallies are driving discussion, with traders parsing technical support and some treating the decline as an accumulation opportunity. Others argue LTC repeatedly gives back gains and may remain under pressure, while bullish breakout and squeeze calls remain speculative.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is drawing attention after traders discussed a Q3 earnings beat and raised 2026 revenue guidance, alongside progress in its cancer pipeline. The reaction is mixed: some see oncology programs such as pumitamig as a growth driver, while others remain cautious about fading COVID revenue and clinical execution risks.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AIs quarterly results beat expectations and the company raised its full-year revenue outlook, prompting a bullish reaction and heavy focus on call-option activity. Traders are debating whether momentum will continue or fade, while some remain cautious about volatility, valuation, and how quickly hospitals will adopt its AI products.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic stake and the startups reported IPO filing have fueled interest in ZM as a public-market proxy, while bulls also point to recent earnings strength. The debate is whether that investment and AI initiatives can offset Zooms modest core growth and competition from bundled workplace tools; skeptics say the stake alone is not enough.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Unusual options and elevated dark-pool activity are drawing attention, with traders noting fresh positioning on both calls and puts and debating whether the put flow reflects hedging or a bearish view. The broader discussion is directionally mixed, with some traders expecting further weakness and others watching for a rebound.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Attention centers on povetacicepts upcoming FDA decision for IgA nephropathy, following positive Phase 3 RAINIER results; traders are bullish on its potential as a new growth pillar, though approval and commercial upside remain uncertain. Q3 results also drew mixed reactions, with revenue growth and raised guidance weighed against an adjusted EPS miss and concerns about valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dauch Corporation (DCH) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Dauch Slips To Loss In Q3, Lifts FY26 Outlook

(RTTNews) - Automotive supplier Dauch Corp. (DCH) on Friday reported a third-quarter loss, compared with a profit a year earlier, despite significantly higher sales. Cost and interest expenses impacted the earnings...

Dauch (DCH) Surpasses Q3 Earnings and Revenue Estimates

Dauch (DCH) delivered earnings and revenue surprises of +57.14% and +6.08%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Dauch Reports Third Quarter 2026 Financial Results

Dauch Reports Third Quarter 2026 Financial Results Dauch Reports Third Quarter 2026 Financial ResultsPR NewswireDETROIT, Nov. 6, 2026 Delivers Strong Operating Cash FlowDETROIT, Nov. 6, 2026 /PRNewswire/ -- Dauch Corporation ("Dauch") (NYSE: DCH; LSE: DCH) today reported its financial results for...

Dauch Corporation Announces Employee Inducement Award Under NYSE Rule 303A.08

Dauch Corporation Announces Employee Inducement Award Under NYSE Rule 303A.08 Dauch Corporation Announces Employee Inducement Award Under NYSE Rule 303A.08PR NewswireDETROIT, Nov. 3, 2026 DETROIT, Nov. 3, 2026 /PRNewswire/ -- Dauch Corporation ("Dauch"), (NYSE: DCH; LSE: DCH) today announced...

Dauch to Announce Third Quarter Financial Results on November 6th

Dauch to Announce Third Quarter Financial Results on November 6th Dauch to Announce Third Quarter Financial Results on November 6thPR NewswireDETROIT, Nov. 2, 2026 DETROIT, Nov. 2, 2026 /PRNewswire/ -- Dauch Corporation, (NYSE: DCH, LSE: DCH) will hold a conference call to discuss third quarter...

Earnings Preview: Dauch (DCH) Q3 Earnings Expected to Decline

Dauch (DCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Phinia (PHIN) Q3 Earnings Top Estimates

Phinia (PHIN) delivered earnings and revenue surprises of +5.17% and -2.37%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Dauch Corporation Announces Financial Leadership Succession Plan and Executive Realignment

Dauch Corporation Announces Financial Leadership Succession Plan and Executive Realignment Dauch Corporation Announces Financial Leadership Succession Plan and Executive RealignmentPR NewswireDETROIT, Oct. 12, 2026Nathan Iles joins as Senior Vice President of Finance with planned transition to...

Dauch to Present at the 2026 Jefferies Global Industrials Conference on September 10

Dauch to Present at the 2026 Jefferies Global Industrials Conference on September 10 Dauch to Present at the 2026 Jefferies Global Industrials Conference on September 10 PR Newswire DETROIT, Sept. 4, 2026 DETROIT, Sept. 4, 2026 /PRNewswire/ -- Dauch Corporation, (NYSE: DCH, LSE: DCH) announced that...

$DCH Q3 &#39;26 Earnings Results &amp; Recap

Dauch Corporation&#39;s updated full-year 2026 sales target is $10.8B, Adjusted EBITDA target is $1.35B, and Adjusted free cash flow target is $270M.

Stocktwits

Dauch Corporation

 Q3 '26 Earnings Results & Recap

Dauch Corporation's updated full-year 2026 sales target is $10.8B, Adjusted EBITDA target is $1.35B, and Adjusted free cash flow target is $270M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Dauch Corporation's updated full-year 2026 sales target is $10.8B, Adjusted EBITDA target is $1.35B, and Adjusted free cash flow target is $270M.

Dauch reported a $45.3M attributable net loss, Adjusted EBITDA at 12.3% of sales versus 13.0%, and identified reduced purchases by GM, Stellantis and Ford and reduced demand for light trucks and SUVs as risks.

Dauch reported sales of $2.91B versus $1.51B, while operating cash flow and Adjusted free cash flow were higher than third-quarter 2025; 2026 synergy benefits target $70M.

Dauch Corp. engages in the manufacture, engineering, design, and validation of driveline systems and related components. It operates through the Driveline and Metal Forming segments. The Driveline segment consists of axles, drive shafts, power transfer units, rear drive modules, and electric and hybrid driveline products and systems for light trucks, service utility vehicles, crossover vehicles, passenger cars, and commercial vehicles. The Metal Forming segment manufactures axle shafts, ring and pinion gears, differential gears, transmission gears, and shafts and suspension components for original equipment manufacturers (OEMs), and Tier 1 automotive suppliers. The company was founded by Richard E. Dauch on March 1, 1994 and is headquartered in Detroit, MI.

Dauch Corp.

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits Polls

$DCH Q3 '26 Earnings Results & Recap

Dauch Corporation's updated full-year 2026 sales target is $10.8B, Adjusted EBITDA target is $1.35B, and Adjusted free cash flow target is $270M.

$DCH Will Dauch hit even its cut $1.350B–$1.375B 2026 EBITDA target as Q4 headwinds build?

✂️ Dauch, a Detroit driveline and metal-forming supplier to automakers, was worth about $1.13B at $4.775 a share at 16:01 ET on October 30, 2026, and it has cut its 2026 Adjusted EBITDA target to $1.350B–$1.375B from $1.360B–$1.425B
🔥 The same filing deepens its full-year 2026 net loss target to $195M–$220M, from the $135M–$200M it set on August 7
🏦 The $260M–$325M Adjusted free cash flow target, which leaves out cash restructuring, acquisition and synergy payments, is to be narrowed closer to its midpoint, while on August 7 unadjusted 2026 free cash flow was targeted at -$105M to -$90M

📅 Next: Full Q3 results come before the open on Friday, November 6, 2026, with a 10:00 a.m. ET call; watch how Q4 is expected to reach the target
Source: SEC 8-K, Oct 30 + Q2 release 8-K, Aug 7

Feed

News

Sentiment

Earnings

Fundamentals

Info

DCH Dauch Corporation

Fundamentals

Latest DCH News